Extracellular vesicles from patients with PAH harbored increased amounts of angiogenic proteins and induced activation of pulmonary endothelial cells and in vitro angiogenesis.
Cross-Sectional (n=90)
Do circulating extracellular vesicles from patients with pulmonary arterial hypertension induce endothelial activation and angiogenesis compared to those from healthy controls?
Extracellular vesicles from patients with PAH promote endothelial activation and angiogenesis in vitro, potentially via the P-selectin-PSGL-1 pathway, highlighting a novel mechanism in PAH pathogenesis.
Objective: Extracellular vesicles (EVs) have the potential to act as intercellular communicators. The aims were to characterize circulating EVs in patients with pulmonary arterial hypertension (PAH) and to explore whether these EVs contribute to endothelial activation and angiogenesis. Approach and Results: Patients with PAH (n=70) and healthy controls (HC; n=20) were included in this cross-sectional study. EVs were characterized and human pulmonary endothelial cells (hPAECs) were incubated with purified EVs. Endothelial cell activity and proangiogenic markers were analyzed. Tube formation analysis was performed for hPAECs, and the involvement of PSGL-1 (P-selectin glycoprotein ligand 1) was evaluated. The numbers of CD62P + , CD144 + , and CD235a EVs were higher in blood from PAH compared with HC. Thirteen proteins were differently expressed in PAH and HC EVs, where complement fragment C1q was the most significantly elevated protein ( P =0.0009) in PAH EVs. Upon EVs-internalization in hPAECs, more PAH compared with HC EVs evaded lysosomes ( P <0.01). As oppose to HC, PAH EVs stimulated hPAEC activation and induced transcription and translation of VEGF-A (vascular endothelial growth factor A; P <0.05) and FGF (fibroblast growth factor; P <0.005) which were released in the cell supernatant. These proangiogenic proteins were higher in patient with PAH plasma compered with HC. PAH EVs induced a complex network of angiotubes in vitro, which was abolished by inhibitory PSGL-1antibody. Anti-PSGL-1 also inhibited EV-induced endothelial cell activation and PAH EV dependent increase of VEGF-A. Conclusions: Patients with PAH have higher levels of EVs harboring increased amounts of angiogenic proteins, which induce activation of hPAECs and in vitro angiogenesis. These effects were partly because of platelet-derived EVs evasion of lysosomes upon internalization within hPAEC and through possible involvement of P-selectin-PSGL-1 pathway.
Khandagale et al. (Thu,) conducted a cross-sectional in Pulmonary arterial hypertension (PAH) (n=90). Extracellular vesicles (EVs) vs. Healthy controls (HC) was evaluated on Endothelial cell activity and proangiogenic markers. Extracellular vesicles from patients with PAH harbored increased amounts of angiogenic proteins and induced activation of pulmonary endothelial cells and in vitro angiogenesis.